Holen Sie sich die Stockscreener-App
1.235
1.20%
-0.015
Schlusskurs vom Vortag:
$1.25
Offen:
$1.25
24-Stunden-Volumen:
449.70K
Relative Volume:
0.30
Marktkapitalisierung:
$284.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-179.82M
KGV:
-0.9286
EPS:
-1.33
Netto-Cashflow:
$-159.16M
1W Leistung:
-9.19%
1M Leistung:
+6.93%
6M Leistung:
+27.32%
1J Leistung:
+28.67%
1-Tages-Spanne:
$1.20
$1.28
1-Wochen-Bereich:
$1.195
$1.37
52-Wochen-Spanne:
$0.6617
$1.55
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Vergleichen Sie GOSS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
1.235 | 284.13M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.90 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.01 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
550.40 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.15 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Gossamer Bio Announces Completion of Enrollment in Registrationa - GuruFocus
Gossamer Bio (GOSS) Wraps Up Enrollment for Phase 3 PAH Study | GOSS Stock News - GuruFocus
Gossamer Bio Announces Completion Of Enrollment In Registrational Phase 3 PROSERA Study For The Treatment Of PAH - MarketScreener
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - New Castle News
Gossamer Bio's Breakthrough PAH Drug Hits Major Milestone: 390 Patients Enrolled in Phase 3 Trial - Stock Titan
Squarepoint Ops LLC Has $65,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Brokers Offer Predictions for Gossamer Bio FY2026 Earnings - Defense World
Two Sigma Investments LP Raises Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rul - GuruFocus
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GOSS Stock News - GuruFocus
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule - marketscreener.com
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
HC Wainwright Increases Earnings Estimates for Gossamer Bio - Defense World
Cantor Fitzgerald Forecasts Gossamer Bio FY2025 Earnings - Defense World
Analyze Gossamer Bio Inc (NASDAQ: GOSS) Before Investing. - Stocksregister
Price T Rowe Associates Inc. MD Has $59,000 Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript - MSN
Wedbush Reiterates “Outperform” Rating for Gossamer Bio (NASDAQ:GOSS) - Defense World
The Goldman Sachs Group Raises Gossamer Bio (NASDAQ:GOSS) Price Target to $8.00 - Defense World
GOSS Stock Update: Analyst Reiterates Outperform Rating | GOSS S - GuruFocus
Gossamer Bio’s Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
Gossamer Bio (GOSS): Goldman Sachs Raises Price Target to $8.00 - GuruFocus
Cantor Fitzgerald maintains Overweight on Gossamer Bio stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains Overweight on Gossamer Bio stock - Investing.com
Earnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecasts By Investing.com - Investing.com Nigeria
Gossamer Bio: Q1 Earnings Snapshot - CT Insider
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ... - Yahoo Finance
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strate - GuruFocus
Transcript : Gossamer Bio, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Earnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecasts - Investing.com Australia
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio earnings beat by $0.03, revenue topped estimates - Investing.com
Gossamer Bio Inc (GOSS) Q1 2025 Earnings: EPS Loss of $0.16 Beats Estimate, Revenue Surges to $9.9 Million - GuruFocus
GOSSAMER BIO Earnings Results: $GOSS Reports Quarterly Earnings - Nasdaq
Gossamer Bio (GOSS) Surpasses Revenue Estimates, Advances Key St - GuruFocus
Gossamer Bio (GOSS) Surpasses Revenue Estimates, Advances Key Studies | GOSS Stock News - GuruFocus
Gossamer Bio, Inc. SEC 10-Q Report - TradingView
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Eagle-Tribune
Gossamer Bio Q1 2025 Earnings Call Transcript - MarketBeat
What To Expect From Gossamer Bio Inc (GOSS) Q1 2025 Earnings - GuruFocus
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 - Eagle-Tribune
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference - The Joplin Globe
Market Highlights: Gossamer Bio Inc (GOSS) Ends on a Low Note at 1.09 - DWinneX
Gossamer Bio Inc: Is GOSS Stock Worth Buying? - Stocksregister
Gossamer Bio (GOSS) Expected to Announce Earnings on Tuesday - Defense World
Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection (GOSS) - Seeking Alpha
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.04%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):